Seeking Alpha
21 Jan 2026, 19:50 UTC · 35w ago
Verdict
Headline takes no side. We score CRVS +0.90 across three claims — strongly bullish.
+0.90strongly bullish
More positive than 95% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
75% of patients on 200 mg soquelitinib BID achieved EASI 75 in phase 1 cohort 4 data for atopic dermatitis.
More positive than 99% of claims this week
Treatment benefits for soquelitinib persisted one month after the treatment ended.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 86% of claims this week
The drug showed improved outcomes for patients who had previously been treated with other therapies.
More positive than 77% of claims this week
Which stocks this story touches
More positive than 95% of ticker scores this week
The company reported highly positive phase 1 data for its drug soquelitinib in treating atopic dermatitis.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Business Wire
18h ago
−41.4%
Price is moving against the score
$12.54 vs $21.41 close before publication (Jan 20) · not market-adjusted
CRVS chart →
